DosOpt

DosOpt optimizes vancomycin dosing in neonates by applying Bayesian pharmacokinetic estimation and target-constrained dose simulation to personalize therapeutic regimens.

Key Features:

• Bayesian Framework: DosOpt employs Bayesian methods to derive individual pharmacokinetic (PK) estimates by integrating population priors with patient-specific therapeutic drug monitoring (TDM) measurements.
• Simulation and Optimization: The tool simulates concentration-time curves and performs target-constrained dose optimization to align administered doses with desired PK targets.
• Verification and Validation: Accuracy was assessed using error metrics and normalized prediction distribution errors on samples simulated from established PK models (e.g., Anderson et al.), and validated on retrospective clinical data comprising 149 treatment episodes with multiple vancomycin concentrations per patient.
• Improved Target Attainment: Incorporation of individual concentration measurements increases the probability of achieving target trough (Ctrough) concentrations; for example, three measurements increased attainment within 10–15 mg/L from 16% to 43%.
• Clinical Relevance: Inclusion of even a single measured concentration improved target attainment compared with retrospective clinical dataset benchmarks.

Scientific Applications:

• Personalized Medicine: Tailors vancomycin dosing regimens to individual neonatal patient data to optimize therapeutic outcomes and minimize adverse effects.
• Pharmacokinetic Modeling: Integrates Bayesian modeling with clinical pharmacokinetics to support dose adjustment decisions in neonates.

Methodology:

Bayesian estimation integrating population priors with patient TDM, simulation of concentration-time profiles, target-constrained dose optimization, and evaluation using error metrics and normalized prediction distribution errors on simulations from PK models (e.g., Anderson et al.); retrospective clinical data (149 treatment episodes) used for validation.